The MALDI-8020 is the latest in a long line of MALDI-TOF products from Shimadzu. This benchtop, linear MALDI-TOF mass spectrometer delivers outstanding performance in a compact footprint, making it an ideal choice for today’s increasingly demanding laboratories.
Read more
A study published in the Journal of Diabetes Science and Technology found that “Quo-Lab met all criteria” and “has no bias compared to the mean of four secondary reference measurement procedures.”*
Quo-Lab is a semi-automated analyser designed to meet the needs of diabetes clinics and labs that demand low cost of operation and ease of use. It provides HbA1c results in four minutes using a small drop of blood.
EKF has developed Quo-Lab in conjunction with industry experts to deliver a product that meets the tightening requirements of NGSP certification and CAP EQA criteria.
Find out what Quo-Lab can do for your practice today.
https://www.ekfdiagnostics.com/quo-lab.html
*Lenters-Westra E, English E. Evaluation of Four HbA1c Point-of-Care Devices Using International Quality Targets: Are They Fit for the Purpose? Journal of Diabetes Science and Technology. 2018; 12: 762-770.
The new valveless Waste Transfer Pump from Fluid Metering, Inc. (FMI) was designed for removal of waste fluid generated by medical diagnostic instrumentation during the process of analysing a variety of patient fluid samples. The waste fluid generally consists of, but is not limited to, a mixture of patient samples (blood components, urine samples etc..) combined with reagents, byproducts of reagent reactions and wash fluids. These fluids can have a broad range of physical characteristics, viscosity, suspended solids, human tissue, blood cells, just to name a few. The valveless, brushless DC Waste Transfer Pump utilizes FMI’s innovative CeramPump valveless piston fluid control technology. One moving part, a rotating and reciprocating ceramic piston accomplishes all fluid control functions within the pump, thereby eliminating the need for check valves present in other reciprocating pump designs (diaphragm, bellows, solenoid piston, syringe). The variety of suspended solids and particulates present in medical instrumentation waste often causes check valves to stick, clog, and eventually fail requiring the pumps to be removed from the system and serviced. The sapphire-hard, dimensionally stable ceramic internal components of the CeramPump also substantially outperforms peristaltic pumps relying on flexible tubing. Peristaltic pumps can have integrity issues as flexible tubing over time wears and needs to be routinely replaced, at best, and at worst, can rupture resulting in bio-contaminants leaking out of the system. FMI’s valveless, brushless DC motor Waste Transfer Pump integrates the long-life performance of a brushless motor, with a built-in driver, together with the advantages of FMI’s CeramPump valveless fluid transfer technology. The pump is easily integrated into any existing system design. All that is needed is a simple 24V DC input supply. Flow rates can be factory calibrated from 20 mL/min to 400 mL/min. The integral compact design with a small 6” x 2” x 2” (approx. 15 x 5 x 5 cm) footprint makes it ideal for medical and analytical instrumentation applications.
Horizon Discovery Group, a global leader in the application of gene editing and gene modulation for cell line engineering, has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays.
Horizon’s OncoSpan range now includes formalin-fixed, paraffin-embedded (FFPE) and cell-free DNA (cfDNA) formats for mimicking solid tumors and liquid biopsy samples, respectively, in addition to its well-established genomic DNA (gDNA) format. Its cfDNA format offers one of the largest number of variants and genes, over 380 and 152 respectively, of any characterized reference standard to help standardize liquid biopsy testing.
These cell-line derived reference standards closely mimic patient samples and offer an unlimited and reproducible resource to help ensure consistency during the establishment and validation of diagnostic assays. All three formats are delivered with batch-specific, next-generation sequencing (NGS) data, orthogonally validated by ddPCR, to allow researchers to further validate their analysis pipeline.
For further information, visit: horizondiscovery.com/en/products/diagnostic-reference-standards/PIFs/OncoSpan-cfDNA
Read more
INTEGRA Biosciences has developed its GripTip pipette tips range to overcome the problems associated with the use of universal pipette tips. Universal pipette tips require hammering on to stretch the tip, often resulting in a suboptimal fit that can lead to loose, leaking and falling off tips. GripTips are designed to offer a perfect fit on INTEGRA pipettes, effortlessly snapping onto the tip fittings with low attachment and ejection forces. This ensures that all tips are at the same height, guaranteeing perfect alignment and seal, even when performing side well touch-offs. They span a wide volume range – from 0.5 to 5000 µl – and are available in sterile, non-sterile and filtered options. The portfolio also includes a number of specialty GripTips, such as low retention tips for recovering viscous solutions, wide bore tips for cellular applications, short tips for improved ergonomics and targeting of small wells, and extra long tips for improved access to tubes. This range is continuously being expanded to ensure that there are GripTips to meet the needs of every customer, for every application. The two latest tips include a 1250 µl short tip – perfect for ergonomically pipet-ting large volumes, by eliminating the need to hold the pipette high over the bench, reducing the risk of RSI – and a 300-µl long tip that, at 102 mm long, enables the user to easily reach the bottom of standard 100 ml tubes. To aid tip selection, INTEGRA has launched its GripTip selector, simply using filters to identify the most suitable tips for the required workflow in seconds.
Abbott has announced CE Mark for the Alinity m diagnostic system and assays that will allow laboratories to meet the growing demand for infectious disease testing by offering increased efficiency, speed and accuracy. This new technology will provide high flexibility in molecular diagnostic testing, allowing more tests to be done in shorter timeframes, while reducing the space and number of instruments needed to conduct large amounts of tests. The World Health Organization (WHO) reports that more than a billion people around the world are living with infectious diseases. For people living with infectious diseases, quick and accurate molecular test results are needed to help prevent the spread of communicable diseases globally. Advanced molecular testing also allows patients to be diagnosed correctly and then monitored for their response to treatment. Molecular laboratories are playing an increasingly important role in providing critical test results for infectious disease diagnosis. Alinity m will significantly improve the way these laboratories operate by letting staff run any sample at any time, without the need to group samples, allowing them to focus on giving physicians the information they need to make accurate, timely clinical decisions. Alinity m provides superior flexibility for lab staff and faster testing results for clinicians and patients. Alinity m may also reduce the lab equipment footprint from four to six instruments down to one – decreasing the space requirements and hours spent learning and maintaining different instruments. Now available in countries that recognize CE Mark, Alinity m offers initial assays including virologic testing for human immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV); sexual health-related testing for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium or CT/NG/TV/MG panel; and high-risk human papillomavirus (HPV) testing. Local product availability may vary depending on geographic location.
ABBOTT
Read more
AMSBIO has introduced StemFit for Differentiation – a new chemically defined and animal component-free formulation that enables unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells.
The unique chemically defined composition of StemFit for Differentiation minimizes lot-to-lot variation, enabling highly consistent cell differentiation. Free of animal- and human-derived components, StemFit for Differentiation can be used to eliminate the risk of immunogenic contamination.
Applications proven to benefit from StemFit for Differentiation include: lineage-specific (endodermal, mesodermal and ectodermal) differentiation where this new product is used to replace serum-free supplements, as well as spontaneous differentiation of hiPSCs to organoids via embryoid body formation.
Used in combination with StemFit Basic feeder-free medium with iMatrix-511 laminin as extracellular matrix, StemFit for Differentiation enables researchers to undertake clinical applications involving both expansion and differentiation of human Pluripotent Stem Cell-derived cells and tissues.
Supplied as a 5X concentrate, StemFit for Differentiation has been formulated for use with basal cell culture medium (e.g. DMEM, RPMI 1640, DMEM/F12 etc.) and a variety of different induction factors or cytokines (including Activin A and bFGF from AMSBIO).
Incorporating a novel dual hydrophobically treated matrix filter, Microlute Protein Precipitation Plate from Porvair Sciences sets a new standard for labs looking to remove interfering proteins from serum, plasma or whole blood samples prior to analysis by Liquid Chromatography / Mass Spectrometry (LC/MS). Biological samples commonly contain proteins that interfere with downstream applications such as LC/MS analysis. Microlute Protein Precipitation Plates (PPP) use the CRASH method, in which protein is denatured with acetonitrile and the flocculant filtered out, allowing 96 samples to be processed in parallel. Based on the industry standard MicroLute format, but without the chromatographic sorbent, protein ‘crashes’ out of solution and precipitates directly in each well when acetonitrile is added, thus solving all common problems associated with the CRASH technique of protein cleanup. The novel dual frit, hydrophobically treated matrix used by the Microlute PPP means that there is no ‘wetting out’ and leakage of sample before the application of vacuum. Due to its ease of use, high performance and reliability the Microlute PPP is commonly used as the protein precipitation plate of choice in many major pharmaceutical companies worldwide. Established in 1992, Porvair Sciences is one of the largest global manufacturers of ultra-clean microplates and top-quality microplate equipment for life science, synthetic chemistry and many other applications.
Read more
TRIMERO has added to its catalogue a new Serum Amyloid A, CE-IVD marked, particle-enhanced turbidimetric immunoassay. Applications are available for the most popular clinical chemistry analysers, and for IMMAGE® nephelometers of Beckman Coulter. In order to ensure lot to lot traceability, the assay has been standardized to the Serum Amyloid A (SAA) 1st International Standard (NIBSC code: 92/680) of the WHO (World Health Organization).
Other available assays for turbidimetry and nephelometry include:
KLoneus® Free Light Chains (FLC), IgD Immunoglobulins, Retinol Binding Protein (RBP) for serum and urine, Soluble Transferrin Receptor (sTfR), Hemopexin, Cystatin-C for serum and urine, A1-Microglobulin, B2-Microglobulin for serum and urine, Kappa and Lambda Light Chains for serum and urine, Complement C1q, Complement C5, Factor B (C3 Proactivator), C1 (Esterase) Inhibitor.
Ansh labs has launched two new immunoassays, SARS-CoV2 IgG and IgM ELISAs, to assist in the fight against the Covid-19 pandemic.
Ansh Labs is releasing these two kits for sale in the United States under the provisions outlined in Section D of Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. At the time of going to press, these tests were under review by the FDA for an Emergency Use Authorization.
IgM antibody is the first to be produced in response to viral proteins (antigens) and will be primarily detectable during the early onset of the disease. IgG antibodies are long-lasting and can persist in the bloodstream for many years after infection. This test has the advantage of detecting not only individuals with active infection (IgM), but also those who were previously exposed to the virus and may have subsequently developed immunity (IgG).
Testing for SARS-CoV2 antibodies can help in epidemiological surveillance about the spread of the virus and possible herd immunity. Ansh Labs’ SARS-CoV2 ELISAs are highly accurate with IgG ELISA offering 96% specificity and IgM ELISA offering 99% specificity.
For more information, visit: www.covid-diagnostics.com
Read more
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
